AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3114808
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg qid
Trial: 3114808
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg each hour
Trial: 29766330
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment alone (Er group)
Trial: 29766330
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with Nd:YAG and Er:YAG lasers (NdErNd group)
Trial: 28162931
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG) - Staged multicomponent tailored behavioral interventions (e.g., electronic monitoring feedback, motivational interviewing)
Trial: 26241254
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 10 mg administered 30-60 minutes before surgical abortion.
Trial: 26241254
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 30-60 minutes before surgical abortion.
Trial: 20803856
Drug: 5 ml*h(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml*h(‐1) ropivacaine 0.2% (study group, n = 21)
Trial: 20803856
Drug: 5 ml*h(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml*h(‐1) saline (control group, n = 21)
Trial: 18763292
Drug: Total parental
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parental nutrition (TPN) in combination with operation
Trial: 11086664
Drug: granisetron 2
RxNorm normalized name: granisetron 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: granisetron 2 mg
Trial: 8828422
Drug: Continuous hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous hormone replacement therapy (first 6 months)
Trial: 8828422
Drug: Suspension of
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of hormone replacement therapy (first 6 months)
Trial: 8828422
Drug: Resumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resumption of hormone replacement therapy (after 6 months)
Trial: 8828422
Drug: Suspension of
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of hormone replacement therapy (after 6 months)
Trial: 1448310
Drug: Miconazole oral
RxNorm normalized name: miconazole Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole oral gel
Trial: 30644628
Drug: Intranasal 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 1.4 mg naloxone
Trial: 30644628
Drug: Intramuscular 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 0.8 mg naloxone
Trial: 30689736
Drug: Anti-PD-1 therapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 therapy (nivolumab)
Trial: 26960919
Drug: Extubation failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extubation failure (adjusted for allocated treatment)
Trial: 22735801
Drug: Intravitreal Triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Triamcinolone Acetonide (4 mg)
Trial: 22735801
Drug: Intravitreal Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Bevacizumab (1.25 mg)
Trial: 10338904
Drug: Salmeterol aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol aerosol 42 micrograms twice daily
Trial: 10338904
Drug: Placebo (as‐needed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (as‐needed albuterol)
Trial: 8275438
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg gabexate mesilate, intravenously twice a day for 5 days after TAE
Trial: 8275438
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg gabexate mesilate
Trial: 2498383
Drug: 4-hour continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hour continuous intravenous infusion of GH (180-micrograms bolus dose, then 3 micrograms/min)
Trial: 2498383
Drug: 6-hour continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-hour continuous intravenous infusion of GH (180-micrograms bolus dose, then 3 micrograms/min)
Trial: 17067136
Drug: Magnesium 40
RxNorm normalized name: Magnesium 400mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium 40 mg x kg(‐1) for 5 min at 6.5 min before induction
Trial: 17067136
Drug: Vecuronium 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.02 mg x kg(‐1) at 1.5 min before induction
Trial: 17067136
Drug: Saline 1-2
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 1-2 ml at 1.5 min before induction
Trial: 8551420
Drug: Reduced osmolarity
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced osmolarity ORS (245 mmol/L sodium and glucose)
Trial: 8551420
Drug: Standard WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard WHO ORS (311 mmol/L)
Trial: 6882881
Drug: Experimental ASA
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental ASA formulation
Trial: 30132262
Drug: Metformin (850-1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850-1700 mg)
Trial: 29980120
Drug: Present Centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present Centered Group Therapy (PCGT)
Trial: 21603629
Drug: Artesunate 2
RxNorm normalized name: Artesunate 25 mg and mefloquine (as mefloquine hydrochloride) 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate 2 mg/kg/day
Trial: 21603629
Drug: Artesunate 4
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 4 mg/kg/day
Trial: 21603629
Drug: Artesunate 6
RxNorm normalized name: artesunate 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate 6 mg/kg/day
Trial: 19000552
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 25 mg pactimibe
Trial: 19000552
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 100 mg pactimibe for 21 days in CYP2D6 PMs
Trial: 9332112
Drug: Intravenous Magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Magnesium sulfate (0.2 ml/kg of 50% MgSO4 as intravenous infusion over 35 minutes)
Trial: 9332112
Drug: Intravenous Magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Magnesium sulfate
Trial: 9332112
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline infusion in the same dose and at the same rate)
Trial: 8441894
Drug: Lozenges
RxNorm normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lozenges
Trial: 3741825
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine (1.5 mg kg‐1)
Trial: 31278470
Drug: Intracutaneous sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous sterile water injection (ISWI)
Trial: 26553486
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg day(-1)
Trial: 26553486
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of standard insulin therapy
Trial: 23753256
Drug: Regular self-weighing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular self-weighing intervention (two telephone calls, offer of free weighing scales, encouragement to weigh weekly)
Trial: 19850640
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intensity doxorubicin-based regimens
Trial: 18226670
Drug: DMPA 150
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA 150 mg intramuscularly
Trial: 11004040
Drug: Bisulfite-containing propofol
RxNorm normalized name: Sodium bisulfite
DrugBank: Sodium bisulfite (DB14015)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisulfite-containing propofol 1.5 mg/kg IV
Trial: 8823692
Drug: Aceclofenac, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac, 100 mg bid orally
Trial: 8823692
Drug: Tenoxicam, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam, 20 mg orally at bedtime
Trial: 1349496
Drug: Celiprolol 200
RxNorm normalized name: celiprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 200 mg daily for 7 days
Trial: 3512461
Drug: Control lotion
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control lotion (vehicle)
Trial: 29558782
Drug: Verum (Monapax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum (Monapax syrup)
Trial: 27382456
Drug: Silymarin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (70 mg) administered at three hours and 24 hours after pregnancy termination
Trial: 27382456
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at three hours and 24 hours after pregnancy termination
Trial: 24802951
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500 mg · day(‐1))
Trial: 22526068
Drug: Cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing green tea extract
Trial: 9569477
Drug: Recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B virus (HBV) vaccines administered at 2, 4, and 12 months of age, concurrent with OPV and DTP vaccination.
Trial: 9569477
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell DTP and three-component acellular DTaPs administered as part of the vaccination schedule.
Trial: 9569477
Drug: Antibody response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibody response measured by ELISA for HBsAg.
Trial: 30661700
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A treatment (100,000 IU intramuscular daily for 7 days)
Trial: 30661700
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (blinded placebo daily for 7 days)
Trial: 29353426
Drug: Dipyrone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (1 g) administered preemptively before surgery
Trial: 29353426
Drug: Dipyrone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (1 g) administered in the immediate postoperative period
Trial: 27898166
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (7- to 14-day regimen with PPI, clarithromycin, and either amoxicillin or an imidazole)
Trial: 27898166
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy (5 days of PPI and amoxicillin followed by 5 days of PPI, clarithromycin, and an imidazole)
Trial: 27898166
Drug: 14-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day sequential therapy (5 days of PPI and amoxicillin followed by 5 days of PPI, clarithromycin, and an imidazole)
Trial: 24055350
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of Q-HPV vaccine at 0, 6 months (n=259)
Trial: 24055350
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of Q-HPV vaccine at 0, 2, 6 months (n=260)
Trial: 24055350
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of Q-HPV vaccine at 0, 2, 6 months (n=305)
Trial: 24055350
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of Q-HPV vaccine (all subjects)
Trial: 18806966
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg SF‐TRE
Trial: 18806966
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg SF‐TRE
Trial: 18806966
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg SF‐TRE
Trial: 16297562
Drug: Current illicit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current illicit drug use (N=253)
Trial: 16297562
Drug: Past drug
RxNorm normalized name: Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Past drug use (N=617)
Trial: 551921
Drug: Specific hypotensive
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific hypotensive therapy (Ht)
Trial: 9230648
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot (3.75 mg once a month for 3 months)
Trial: 3677283
Drug: Neostigmine, 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine, 0.04 mg.kg‐1
Trial: 3677283
Drug: Pyridostigmine, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine, 0.2 mg.kg‐1
Trial: 3677283
Drug: Edrophonium, 0.54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium, 0.54 mg.kg‐1
Trial: 29198157
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol valerate daily plus 4 mg medroxyprogesterone acetate on days 19–30
Trial: 29198157
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol valerate daily plus 100 mg micronized progesterone on days 19–30
Trial: 27716201
Drug: CRP <
RxNorm normalized name: Corticotropin-releasing protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP < 5 mg/L
Trial: 18031594
Drug: Oral bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisphosphonates (alendronate, risedronate, ibandronate)
Trial: 18031594
Drug: Etidronate (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (administered with an extended between-dose interval)
Trial: 18031594
Drug: Non-daily oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-daily oral bisphosphonates
Trial: 15731977
Drug: Information group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information group (oral and written information about baby blues and postpartum depression)
Trial: 10229740
Drug: Argatroban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (10 mg/d IV) over 2 hours for 7 days
Trial: 9367941
Drug: Drug formulation
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug formulation containing dimethylaminoethanolorotrate (DMAE), vitamins and minerals, 1 capsule per day for 12 weeks
Trial: 12620603
Drug: Propranolol (beta-blocker)
RxNorm normalized name: beta-Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (beta-blocker)
Trial: 19409854
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (200 mg)
Trial: 9754457
Drug: Neural network
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neural network model for predicting heparin concentrations
Trial: 9754457
Drug: NONMEM model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NONMEM model for predicting heparin concentrations
Trial: 1882908
Drug: Sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2 g, twice daily (b.i.d. group)
Trial: 1882908
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g, four times daily (q.i.d. group)
Trial: 786314
Drug: Viloxazine (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine (150-300 mg/day)
Trial: 30288563
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin (0.5 mg/kg) started on the 31st day after surgery, given every other day for 1 month and then daily for two additional months
Trial: 26490434
Drug: Ongoing LMWH
RxNorm normalized name: Ongo-Fin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing LMWH treatment for CAT
Trial: 26490434
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of LMWH at 6 months' treatment
Trial: 24111502
Drug: n‐3 LCPUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 LCPUFA supplementation (fish oil capsules providing 900 mg daily)
Trial: 24111502
Drug: Control (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (matched vegetable oil capsules without n‐3 LCPUFA)
Trial: 24111502
Drug: n‐3 LCPUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 LCPUFA supplementation (fish oil capsules)
Trial: 24111502
Drug: Control (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (matched vegetable oil capsules)
Trial: 18786624
Drug: UDB 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDB 0.06 mg
Trial: 18786624
Drug: UDB 0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDB 0.12 mg
Trial: 18786624
Drug: UDB 0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDB 0.24 mg
Trial: 18786624
Drug: Commercial budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercial budesonide 0.25 mg
Trial: 15791100
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (100 mg/kg before incision and 10 mg/kg/h during surgery)
Trial: 11809113
Drug: Octreotide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.1 mg IV injection + continuous drip at 25 microg/h for 24 hours)
Trial: 11809113
Drug: Octreotide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.1 mg IV injection + continuous drip at 42 microg/h for 24 hours)
Trial: 11809113
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg IV injection + continuous drip at 8 mg/h for 24 hours)
Trial: 11809113
Drug: Octreotide (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (same dosage as in group 1 for 72 hours)
Trial: 11809113
Drug: Omeprazole (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (same dosage as in group 3 for 72 hours)
Trial: 2896866
Drug: Intravenous desferrioxamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous desferrioxamine 1 g at the end of each dialysis for six months
Trial: 28814805
Drug: Intercalating gefitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercalating gefitinib (250 mg/day on days 15-25 of each cycle until disease progression)
Trial: 28814805
Drug: Chemotherapy (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (gemcitabine 1250 mg/m2 plus carboplatin 5 AUC)
Trial: 26091193
Drug: Asenapine 2.5
RxNorm normalized name: asenapine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 2.5 mg b.i.d.
Trial: 26091193
Drug: Asenapine 5
RxNorm normalized name: asenapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 5 mg b.i.d.
Trial: 26598478
Drug: Asenapine 10
RxNorm normalized name: asenapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 10 mg b.i.d.
Trial: 26598478
Drug: Asenapine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine (all doses)
Trial: 23578031
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg
Trial: 23578031
Drug: Prednisolone 10
RxNorm normalized name: prednisolone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 10 mg daily
Trial: 19692802
Drug: Peroperatively applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroperatively applied local doses of a mix containing corticosteroids